Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
How to buy AbCellera Biologics stock | $15.97
Learn how to easily invest in AbCellera Biologics stock.
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
How to buy shares in AbCellera Biologics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
AbCellera Biologics stock price (NASDAQ: ABCL)Use our graph to track the performance of ABCL stocks over time.
AbCellera Biologics shares at a glance
|Latest market close||$15.97|
|52-week range||$14.51 - $71.91|
|50-day moving average||$18.10|
|200-day moving average||$22.13|
|Wall St. target price||$45.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.74|
Buy AbCellera Biologics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy AbCellera Biologics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AbCellera Biologics price performance over time
|1 week (2021-10-14)||0.38%|
|1 month (2021-09-21)||-24.24%|
|3 months (2021-07-21)||-3.91%|
|6 months (2021-04-21)||-45.04%|
|1 year (2020-10-17)||N/A|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
Is AbCellera Biologics under- or over-valued?
Valuing AbCellera Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbCellera Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbCellera Biologics's P/E ratio
AbCellera Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, AbCellera Biologics shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, AbCellera Biologics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
AbCellera Biologics's EBITDA
AbCellera Biologics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $322.1 million.
The EBITDA is a measure of a AbCellera Biologics's overall financial performance and is widely used to measure a its profitability.
To put AbCellera Biologics's EBITDA into context you can compare it against that of similar companies.
AbCellera Biologics financials
|Revenue TTM||$447.7 million|
|Operating margin TTM||69.67%|
|Gross profit TTM||$176.6 million|
|Return on assets TTM||29.83%|
|Return on equity TTM||43.31%|
|Market capitalisation||$4.3 billion|
TTM: trailing 12 months
Shorting AbCellera Biologics shares
There are currently 8.1 million AbCellera Biologics shares held short by investors – that's known as AbCellera Biologics's "short interest". This figure is 3.3% up from 7.9 million last month.
There are a few different ways that this level of interest in shorting AbCellera Biologics shares can be evaluated.
AbCellera Biologics's "short interest ratio" (SIR)
AbCellera Biologics's "short interest ratio" (SIR) is the quantity of AbCellera Biologics shares currently shorted divided by the average quantity of AbCellera Biologics shares traded daily (recently around 3.3 million). AbCellera Biologics's SIR currently stands at 2.48. In other words for every 100,000 AbCellera Biologics shares traded daily on the market, roughly 2480 shares are currently held short.
To gain some more context, you can compare AbCellera Biologics's short interest ratio against those of similar companies.
However AbCellera Biologics's short interest can also be evaluated against the total number of AbCellera Biologics shares, or, against the total number of tradable AbCellera Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbCellera Biologics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AbCellera Biologics shares in existence, roughly 30 shares are currently held short) or 0.0458% of the tradable shares (for every 100,000 tradable AbCellera Biologics shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbCellera Biologics.
Find out more about how you can short AbCellera Biologics stock.
AbCellera Biologics share dividends
We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.
AbCellera Biologics overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics in the news
Could The AbCellera Biologics Inc. (NASDAQ:ABCL) Ownership Structure Tell Us Something Useful?
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
AbCellera Biologics : to Report Third Quarter 2021 Financial Results on November 9, 2021
Frequently asked questionsWhat percentage of AbCellera Biologics is owned by insiders or institutions?
Currently 31.505% of AbCellera Biologics shares are held by insiders and 47.913% by institutions. How many people work for AbCellera Biologics?
Latest data suggests 302 work at AbCellera Biologics. When does the fiscal year end for AbCellera Biologics?
AbCellera Biologics's fiscal year ends in December. Where is AbCellera Biologics based?
AbCellera Biologics's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 What is AbCellera Biologics's ISIN number?
AbCellera Biologics's international securities identification number is: CA00288U1066
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert